CO4970793A1 - Composicion para dispersion molecular con biodisponibilidad aumentada - Google Patents

Composicion para dispersion molecular con biodisponibilidad aumentada

Info

Publication number
CO4970793A1
CO4970793A1 CO98075234A CO98075234A CO4970793A1 CO 4970793 A1 CO4970793 A1 CO 4970793A1 CO 98075234 A CO98075234 A CO 98075234A CO 98075234 A CO98075234 A CO 98075234A CO 4970793 A1 CO4970793 A1 CO 4970793A1
Authority
CO
Colombia
Prior art keywords
composition
molecular dispersion
increased bioavailability
molecular
dispersion
Prior art date
Application number
CO98075234A
Other languages
English (en)
Inventor
A Sangekar Surendra
I Lee Ping
Amin Nomeir
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO4970793A1 publication Critical patent/CO4970793A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe una composición para dispersión molecular. La dispersión molecular comprende a un compuesto de la fórmula: (I)molecularmente disperso en una matriz polimérica. También se describen la forma de dosificación sólidas por ejemplo, tabletas y cápsulas, que contienen a estas dispersiones moleculares.
CO98075234A 1997-12-22 1998-12-17 Composicion para dispersion molecular con biodisponibilidad aumentada CO4970793A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99716897A 1997-12-22 1997-12-22

Publications (1)

Publication Number Publication Date
CO4970793A1 true CO4970793A1 (es) 2000-11-07

Family

ID=25543717

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98075234A CO4970793A1 (es) 1997-12-22 1998-12-17 Composicion para dispersion molecular con biodisponibilidad aumentada

Country Status (28)

Country Link
EP (1) EP1039908B1 (es)
JP (2) JP2001526227A (es)
KR (1) KR100597331B1 (es)
CN (1) CN1116039C (es)
AR (1) AR017436A1 (es)
AT (1) ATE260105T1 (es)
AU (1) AU761994C (es)
BR (1) BR9813728A (es)
CA (1) CA2315685C (es)
CO (1) CO4970793A1 (es)
CZ (1) CZ295956B6 (es)
DE (1) DE69821984T2 (es)
DK (1) DK1039908T3 (es)
ES (1) ES2214757T3 (es)
HK (1) HK1027040A1 (es)
HU (1) HU229052B1 (es)
ID (1) ID28304A (es)
IL (1) IL136460A0 (es)
MY (1) MY126580A (es)
NO (1) NO327383B1 (es)
NZ (1) NZ504834A (es)
PE (1) PE20000012A1 (es)
PL (1) PL192423B1 (es)
PT (1) PT1039908E (es)
SK (1) SK285662B6 (es)
TW (1) TW527196B (es)
WO (1) WO1999032118A1 (es)
ZA (1) ZA9811592B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
EP1404300B1 (en) 2001-06-22 2009-09-30 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
EP1492508A4 (en) * 2002-03-04 2009-05-06 Teva Pharma DOSAGE FORMS WITH CONTROLLED RELEASE
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
PT103661B (pt) 2007-02-23 2010-09-07 Hovione Farmaciencia S A Processo de preparação de minociclina base cristalina
WO2008136392A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. 経口投与用製剤
US8835635B2 (en) * 2012-06-05 2014-09-16 Symed Labs Limited Amorphous form of vilazodone hydrochloride substantially free of crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
EP0214092A1 (en) * 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
DE69222182T2 (de) * 1991-12-18 1998-02-26 Warner Lambert Co Verfahren für die herstellung einer festen dispersion
JPH0848632A (ja) * 1994-08-08 1996-02-20 Kanebo Ltd エトポシドを含有する固形組成物および固形製剤
TW350844B (en) * 1995-12-22 1999-01-21 Schering Corp Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases
ES2224256T3 (es) * 1996-06-28 2005-03-01 Schering Corporation Disolucion solida de un agente antifungico con biodisponibilidad mejorada.

Also Published As

Publication number Publication date
EP1039908B1 (en) 2004-02-25
NO20003235D0 (no) 2000-06-21
EP1039908A1 (en) 2000-10-04
CZ20002304A3 (cs) 2001-04-11
SK8962000A3 (en) 2001-07-10
CZ295956B6 (cs) 2005-12-14
KR20010033397A (ko) 2001-04-25
DK1039908T3 (da) 2004-05-03
KR100597331B1 (ko) 2006-07-10
AU761994C (en) 2004-01-08
ZA9811592B (en) 1999-06-17
SK285662B6 (sk) 2007-05-03
WO1999032118A1 (en) 1999-07-01
AU761994B2 (en) 2003-06-12
ID28304A (id) 2001-05-10
NO20003235L (no) 2000-07-27
CA2315685A1 (en) 1999-07-01
JP2010059212A (ja) 2010-03-18
DE69821984T2 (de) 2004-12-30
CA2315685C (en) 2008-02-05
PE20000012A1 (es) 2000-01-18
PL341344A1 (en) 2001-04-09
ES2214757T3 (es) 2004-09-16
HU229052B1 (en) 2013-07-29
ATE260105T1 (de) 2004-03-15
CN1116039C (zh) 2003-07-30
PT1039908E (pt) 2004-06-30
BR9813728A (pt) 2000-10-10
MY126580A (en) 2006-10-31
CN1282245A (zh) 2001-01-31
NZ504834A (en) 2001-12-21
DE69821984D1 (de) 2004-04-01
IL136460A0 (en) 2001-06-14
NO327383B1 (no) 2009-06-22
AU1814399A (en) 1999-07-12
HK1027040A1 (en) 2001-01-05
AR017436A1 (es) 2001-09-05
HUP0100850A2 (hu) 2001-10-28
PL192423B1 (pl) 2006-10-31
TW527196B (en) 2003-04-11
JP2001526227A (ja) 2001-12-18
HUP0100850A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
BRPI0109198B8 (pt) emplastro tendo um apoio
BR9900610A (pt) Polìmeros com unidades de maleimida n-substituìda e sua aplicação em misturas sensìveis à radiação.
CO5060503A1 (es) Formulaciones farmaceuticas
ITRM940621A0 (it) "composizione farmaceutica stabilizzata, relativo solvente e procedimento di preparazione"
TR200100666T2 (tr) Hemen yayılan tablet.
DE69738300D1 (de) Pharmazeutische zusammensetzungen mit verzoegerter freisetzung, die wasserunloesliche komplexverbindungen enthalten
BR9910481A (pt) Composição farmacêutica para comprimido de liberação não-contìnua
CO4970793A1 (es) Composicion para dispersion molecular con biodisponibilidad aumentada
NO953767D0 (no) Tverrbundet amylose som et binde-/opplösende middel i tabletter
BR9814756A (pt) Composição sólida seca para liberação de droga, processo para a preparação da mesma, uso de um grande número de pequenas esferas que contêm uma matriz polimérica composta de um polietileno glicol ou de uma mistura de polietileno glicóis
MY118828A (en) Substituted amino compounds and their use as substances having an analgesic effect
BR0008732A (pt) Métodos para detectar atividade de caspase derivada de membrana e seus moduladores
ES2181168T3 (es) Mezclas solidas a base de sulfonilureas y adyuvantes.
TR200101337T2 (tr) Değiştirilmiş salımlı ensülin sensitizörü için farmasötik terkip ve kullanımı.
CA2317954A1 (fr) Dispositif d'enrobage pour granules a absorber par voie orale
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
NO20010537L (no) Farmasøytiske preparater omfattende ibuprofen og domperidon
ES2171018T3 (es) Uso de agentes inmunomoduladores.
BR9814127A (pt) Nova forma de dosagem oral para carvedilol
EP1186292A3 (de) Feste Zubereitungen mit einer Multi-Kern Struktur
ECSP982794A (es) Composicion para dispersion molecular con biodisponibilidad aumentada
EA200000112A1 (ru) Новая композиция
ID21282A (id) Senyawa-senyawa cincin beranggota-5 terpadu yang disubstitusi sulfonamida, penggunaannya sebagai obat, dan sediaan farmasi yang mengandung senyawa tersebut
ES2185666T3 (es) Formulacion estabilizada para comprimidos.
BR0112878A (pt) Composição farmacêutica tendo atividade especìfica em água